DLA Piper LLP (US)

DLA Piper LLP (US)’s product liability team is a trusted defender of global pharma and medical device companies, having successfully handled numerous high-stakes disputes. It has defended or ended several mass torts through resolution, dispositive preemption, Daubert hearings, and other motions. Leveraging its cross-practice expertise, the team collaborates closely with appellate, regulatory, and life science partners. Atlanta-based Christopher Campbell, co-chair of the product liability group, leads high-profile matters such as Bayer’s global Essure litigation and its phenylephrine cough-cold MDL litigation. Ilana Eisenstein, chair of US litigation based in Philadelphia, specializes in complex issues, developing and managing legal strategy. In New York, Loren Brown chairs the wider US disputes practice and leads the firm’s representation of Novo Nordisk as national trial counsel in litigation related to diabetes and obesity medications Ozempic, Wegovy, and Rybelsu. Boston-based Matthew Holian is another key figure in the practice, frequently serving as national counsel in complex, multi-jurisdictional matters. ‘Client-focused’ Katie Insogna, also in Boston, is ’outstanding at managing the intricacies of a day-to-day high-stakes mass tort’, while New York’s Lucas Przymusinski leverages his medical background to drive legal strategy. Meanwhile, Steve Huffaker, who joined the Austin office from King & Spalding LLP in September 2024, focuses on mass tort coordination and strategy, early case resolution, group settlements, litigation risk strategy, and fact and expert witness development and discovery.